{"id":427,"date":"2012-07-01T00:00:01","date_gmt":"2012-07-01T00:00:01","guid":{"rendered":"https:\/\/awge.doctime.es\/?p=427"},"modified":"2016-05-24T08:20:40","modified_gmt":"2016-05-24T06:20:40","slug":"awge-9","status":"publish","type":"post","link":"https:\/\/awge.doctime.es\/index.php\/2012\/07\/01\/awge-9\/","title":{"rendered":"Effect of iron supplementation on fatigue in nonanemicmenstruating women with low ferritin: a randomizedcontrolled trial"},"content":{"rendered":"

CMAJ
\nPaul Vaucher DiO MSc, Pierre-Louis Druais MD, Sophie Waldvogel MD, Bernard Favrat MD
\nAcceso al enlace publicador<\/a><\/p>\n

Background: The true benefit of iron supplementation
\nfor nonanemic menstruating
\nwomen with fatigue is unknown. We studied
\nthe effect of oral iron therapy on fatigue and
\nquality of life, as well as on hemoglobin, ferritin
\nand soluble transferrin receptor levels, in
\nnonanemic iron-deficient women with unexplained
\nfatigue.
\nMethods: We performed a multicentre, parallel,
\nrandomized controlled, closed-label,
\nobserver-blinded trial. We recruited from the
\npractices of 44 primary care physicians in
\nFrance from March to July 2006. We randomly
\nassigned 198 women aged 18\u201353 years
\nwho complained of fatigue and who had a
\nferritin level of less than 50 ug\/L and hemoglobin
\ngreater than 12.0 g\/dL to receive
\neither oral ferrous sulfate (80 mg of elemental
\niron daily; n = 102) or placebo (n = 96) for
\n12 weeks. The primary outcome was fatigue
\nas measured on the Current and Past Psychological
\nScale. Biological markers were measured
\nat 6 and 12 weeks.
\nResults: The mean score on the Current and Past
\nPsychological scale for fatigue decreased by
\n47.7% in the iron group and by 28.8% in the
\nplacebo group (\u201318.9%, 95%CI \u201334.5 to \u20133.2;
\np = 0.02), but there were no significant effects
\non quality of life (p = 0.2), depression (p = 0.97)
\nor anxiety (p = 0.5). Compared with placebo,
\niron supplementation increased hemoglobin
\n(0.32 g\/dL; p = 0.002) and ferritin (11.4 \u00ecg\/L; p <
\n0.001) and decreased soluble transferrin receptor
\n(\u20130.54 mg\/L; p < 0.001) at 12 weeks.
\nInterpretation: Iron supplementation should
\nbe considered for women with unexplained
\nfatigue who have ferritin levels below 50 \u00ecg\/L.
\nWe suggest assessing the efficiency using
\nblood markers after six weeks of treatment.
\nTrial registration no. EudraCT 2006\u2013000478\u201356.<\/p>\n","protected":false},"excerpt":{"rendered":"